ADA: Novo Nordisk's Big Hopes For Victoza Follow-On's Weight Loss Benefits
Executive Summary
Novo Nordisk AS's semaglutide has the potential to rule the GLP-1 space for treatment of type 2 diabetes because of its strong efficacy and greater effects on weight loss, Chief Medical Officer Alan Moses said during the 2016 American Diabetes Association annual conference, where the company reported updates from the ongoing Phase III SUSTAIN clinical trial program.
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.